Company: PTPI
Filing Date: 2025-03-07
Form Type: PRE 14A
Source: 0001104659-25-021794
Chunk: 78

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-03-07
Form: PRE 14A
Chunk 78
---
 and shares of Common Stock subject to outstanding grants under the Prior Plans that terminate, expire or are cancelled, forfeited, exchanged or surrendered without having been exercised, vested or paid in shares after the Effective Date shall be added to the shares reserved under the Plan. The aggregate number of shares of Common Stock that may be issued or transferred under the Plan pursuant to Incentive Stock Options granted on and after the Effective Date shall not exceed1,002,760,000 shares of Common Stock.

2. This
Amendment shall be effective on the date first set forth above. In the event stockholder approval of this Amendment is not obtained
within twelve (12) months of the date the Board approved this Amendment, the additional shares added to the Plan pursuant to this Amendment
shall not be available for grant as Incentive Stock Options.

3. Except
as expressly amended by this Amendment, the Plan shall continue in full force and effect in accordance with the provisions thereof.

<div align='center'>[Signature page follows.]

B-1</div>

IN WITNESS WHEREOF, the Company has caused this Amendment to be duly executed as of the date first written above.

| Petros                
 Pharmaceuticals, Inc. |                       |
| By:                   |                       |
| Name:                 | Joshua Silverman      |
| Title:                | Chairman of the Board |

<div align='center'>B-2</div>

ANNEX C

<div align='center'>PETROS PHARMACEUTICALS, INC.

Amended and Restated</div>

The purpose of the Petros Pharmaceuticals, Inc.
Amended and Restated 2020 Omnibus Incentive Compensation Plan (the “”) is to provide employees of Petros Pharmaceuticals, Inc.
(the “”) and its subsidiaries, certain consultants and advisors who perform services for the Company or its
subsidiaries,and non-employee members of the Board of Directors of the Company with the opportunity to receive grants of incentive
stock options, nonqualified stock options, stock appreciation rights, stock awards, stock units and other stock-based awards.

The Plan is a successor to the Neurotrope, Inc.
2017 Equity Incentive Plan and the 2013 Equity Incentive Plan, as amended as of July 23, 2014 and further amended as of November 21,
2016 (collectively, the “”). No additional grants have been or will be made under the Prior Plans on and
after the Effective Date. Outstanding grants under the Prior Plans shall continue in effect